David J Cohen

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

J. Dering, R. Finn, D. Slamon, 2009, Breast Cancer Research.

Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

J. Christensen, R. Finn, C. Britten, 2012, Molecular Cancer Therapeutics.

Preclinical Development Dacomitinib ( PF-00299804 ) , an Irreversible Pan-HER Inhibitor , Inhibits Proliferation of HER 2-Ampli fi ed Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

J. Christensen, R. Finn, C. Britten, 2012 .

Loss of TXNIP enhances peritoneal metastasis and can be abrogated by dual TORC1/2 inhibition

R. Shakya, James L. Chen, David J Cohen, 2018, Oncotarget.

Autophagy Induction Results in Enhanced Anoikis Resistance in Models of Peritoneal Disease

T. Bekaii-Saab, K. Selvendiran, James L. Chen, 2016, Molecular Cancer Research.